mhurhangee/patent-ind-claim-en huggingface dataset:
A polymerizable liquid used for producing three-dimensional objects by methods of additive manufacturing, said polymerizable liquid comprising: (a) a blocked or reactively blocked polyurethane prepolymer; (b) (optional) a reactive diluent; (c) a blocked or reactively blocked curing agent; (d) a photoinitiator; and (e) (optional) a blocked or reactively blocked diisocyanate. (a) a blocked or reactively blocked polyurethane prepolymer; (b) (optional) a reactive diluent; (c) a blocked or reactively blocked curing agent; (d) a photoinitiator; and (e) (optional) a blocked or reactively blocked diisocyanate.
A medical tube for intrapelvic treatment of urinary incontinence comprising atubular main body having an internal space in which an implant main body can be inserted and the tubular main body having a curved central portion (S4), and at least part of the central portion (S4) having a circular arc shape; the medical tube wherein the main body has a flattened circle shape including a minor axis (J31) in the direction of a front surface (A3) and a back surface (A4) and a major axis (J32) in the direction of an inner circumferential portion (A1) and an outer circumferential portion (A2) as a cross-sectional shape at the central portion (S4), the inner circumferential portion (A1) and the outer circumferential portion (A2) are located to be space from each other in the direction of a center axis (J5) of the circular arc, and characterized in that the angle (θ1) formed between the minor axis (J31) and a plane (f9) containing both a center point (O) of the circular arc of the central portion (S4) and a center point of the cross-sectional shape of the central portion (S4) and a longitudinal direction of the main body at the central portion (S4) is an acute angle (θ1).
A method for requesting data retransmission performed by a base station , the method comprising: a.) receiving, in a data transmission from a user equipment to the base station , data from the user equipment , b.) determining that a retransmission of the received data may be required, and subsequently sending an ALMOST-ACK signal to the user equipment , wherein the ALMOST-ACK signal indicates to the user equipment that the base station has not fully determined whether a retransmission of the received data is required and that the retransmission is to be delayed until it is determined that the retransmission is required, wherein the ALMOST-ACK signal is not explicitly distinguished from an ACK signal and every ALMOST-ACK signal is considered an ALMOST-ACK signal until a subsequent ACK signal is received, c.) determining that the retransmission is required by receiving information from a backhaul network indicating that the data were dropped in the backhaul network, thereby detecting a failure to route the received data upstream, d.) subsequently sending a RENACK signal to the user equipment , wherein the RENACK signal indicates that the received data are to be retransmitted by the user equipment to the base station . a.) receiving, in a data transmission from a user equipment to the base station , data from the user equipment , b.) determining that a retransmission of the received data may be required, and subsequently sending an ALMOST-ACK signal to the user equipment , wherein the ALMOST-ACK signal indicates to the user equipment that the base station has not fully determined whether a retransmission of the received data is required and that the retransmission is to be delayed until it is determined that the retransmission is required, wherein the ALMOST-ACK signal is not explicitly distinguished from an ACK signal and every ALMOST-ACK signal is considered an ALMOST-ACK signal until a subsequent ACK signal is received, c.) determining that the retransmission is required by receiving information from a backhaul network indicating that the data were dropped in the backhaul network, thereby detecting a failure to route the received data upstream, d.) subsequently sending a RENACK signal to the user equipment , wherein the RENACK signal indicates that the received data are to be retransmitted by the user equipment to the base station .
A container with a wireless IC tag comprising: a container body and a sealing member for sealing an opening portion of the container body; and a wireless IC tag and a cap seal attached to the container, wherein the container body includes a neck that extends from the opening portion, wherein, the wireless IC tag includes an antenna for contactless communication, a wiring for wire break detection, and an IC chip connected to the antenna and the wiring, the cap seal includes a cylindrical member that surrounds the neck, the cylindrical member having a metal section disposed on a side face of the neck, and the wireless IC tag is disposed to extend between opposite lateral sides of the neck via the sealing member, and is partially sandwiched between the neck and the cylindrical member with the IC chip being exposed from the cap seal, and characterised in that the cap seal includes a top face that is connected to a first end, which is one of two axial ends of the cylindrical member, and closes the cylindrical member at the first end, and the cylindrical member includes at least one insulating section extending from the first end, and the metal section and the insulating section are joined to each other to form a closed annular shape in a circumferential direction of the cylindrical member. a container body and a sealing member for sealing an opening portion of the container body; and a wireless IC tag and a cap seal attached to the container, wherein the container body includes a neck that extends from the opening portion, wherein, the wireless IC tag includes an antenna for contactless communication, a wiring for wire break detection, and an IC chip connected to the antenna and the wiring, the cap seal includes a cylindrical member that surrounds the neck, the cylindrical member having a metal section disposed on a side face of the neck, and the wireless IC tag is disposed to extend between opposite lateral sides of the neck via the sealing member, and is partially sandwiched between the neck and the cylindrical member with the IC chip being exposed from the cap seal, and characterised in that the cap seal includes a top face that is connected to a first end, which is one of two axial ends of the cylindrical member, and closes the cylindrical member at the first end, and the cylindrical member includes at least one insulating section extending from the first end, and the metal section and the insulating section are joined to each other to form a closed annular shape in a circumferential direction of the cylindrical member.
A vascular delivery device for introduction into a vasculature, the vascular delivery device comprising: an inner expandable member ; an outer drug delivery component comprising a drug infusible layer configured to be infused with a therapeutic agent while located in the vasculature and being associated with the inner expandable member ; and an infusion lumen in fluid communication with the drug infusible layer , the infusion lumen being configured to transport the therapeutic agent to the drug infusible layer , wherein the inner expandable member and the outer drug delivery component are evertable, the device being configured such that upon pressurization of the inner expandable member , the inner expandable member and the drug delivery component evert and extend through a lumen of a vessel. an inner expandable member ; an outer drug delivery component comprising a drug infusible layer configured to be infused with a therapeutic agent while located in the vasculature and being associated with the inner expandable member ; and an infusion lumen in fluid communication with the drug infusible layer , the infusion lumen being configured to transport the therapeutic agent to the drug infusible layer , wherein the inner expandable member and the outer drug delivery component are evertable, the device being configured such that upon pressurization of the inner expandable member , the inner expandable member and the drug delivery component evert and extend through a lumen of a vessel.
A steering spindle , comprising: a hollow outer tube having a lengthening section and an attachment section , the attachment section having a transition portion and a connection portion , the lengthening section adjoining the attachment section at an end of the transition portion , the transition portion being between the lengthening section and the connection portion , an outer diameter of the connection portion being smaller than an outer diameter of the lengthening section , the lengthening section having first and second portions , the second portion being between the first portion and the transition portion , the outer tube terminating at an end of the connection portion ; and a hollow inner tube press-fit into the outer tube , an end of the inner tube being adjacent the end of the transition portion , the inner tube not extending into the attachment section , the inner tube not extending into the first portion , a length of the second portion being at least equal to a length of the inner tube . a hollow outer tube having a lengthening section and an attachment section , the attachment section having a transition portion and a connection portion , the lengthening section adjoining the attachment section at an end of the transition portion , the transition portion being between the lengthening section and the connection portion , an outer diameter of the connection portion being smaller than an outer diameter of the lengthening section , the lengthening section having first and second portions , the second portion being between the first portion and the transition portion , the outer tube terminating at an end of the connection portion ; and a hollow inner tube press-fit into the outer tube , an end of the inner tube being adjacent the end of the transition portion , the inner tube not extending into the attachment section , the inner tube not extending into the first portion , a length of the second portion being at least equal to a length of the inner tube .
Flushing cistern , in particular a flush-mounted cistern, for a WC or urinal, - with a drain valve which has a closure body which can be lifted from a closed position into a flushing position, wherein the closure body is designed as an overflow pipe and has a seal which, in the closed position, rests tightly on a valve seat , - with at least one water intake line , - with a valve arrangement for letting in drinking water present in the water intake line , - with a water discharge line for discharging the drinking water let in by the valve arrangement, and - with a control, wherein a sensor for measuring the water temperature in the water intake line and/or a sensor for detecting a drinking water withdrawal from a cold water or hot water line connected to the water intake line in the mounted state of the flushing cistern are/is assigned to the control, the sensor for detecting a drinking water withdrawal activating a time measuring device in the case of a detected drinking water withdrawal, wherein the control generates a control signal for actuating the valve arrangement as a function of a sensor signal of the sensor for measuring the water temperature and/or when a predetermined time interval since a last detected drinking water withdrawal is exceeded, wherein the valve arrangement lets in drinking water from the water intake line in dependence on the control signal, and wherein the water discharge line is designed in such a way that it discharges the drinking water let in by the valve arrangement directly into the overflow pipe . - with a drain valve which has a closure body which can be lifted from a closed position into a flushing position, wherein the closure body is designed as an overflow pipe and has a seal which, in the closed position, rests tightly on a valve seat , - with at least one water intake line , - with a valve arrangement for letting in drinking water present in the water intake line , - with a water discharge line for discharging the drinking water let in by the valve arrangement, and - with a control, wherein a sensor for measuring the water temperature in the water intake line and/or a sensor for detecting a drinking water withdrawal from a cold water or hot water line connected to the water intake line in the mounted state of the flushing cistern are/is assigned to the control, the sensor for detecting a drinking water withdrawal activating a time measuring device in the case of a detected drinking water withdrawal, wherein the control generates a control signal for actuating the valve arrangement as a function of a sensor signal of the sensor for measuring the water temperature and/or when a predetermined time interval since a last detected drinking water withdrawal is exceeded, wherein the valve arrangement lets in drinking water from the water intake line in dependence on the control signal, and wherein the water discharge line is designed in such a way that it discharges the drinking water let in by the valve arrangement directly into the overflow pipe .
A method of determining whether a patient having a proneural glioblastoma is likely to respond to treatment with a VEGF antagonist, the method comprising: (a) detecting expression of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2 in a biological sample obtained from the patient prior to administration of a VEGF antagonist to the patient; and (b) comparing the expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2 to a reference expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2, wherein a change in the level of expression of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2 in the patient sample relative to the reference level identifies a patient who is likely to respond to treatment with a VEGF antagonist, wherein the change in the level of expression of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2 in the patient sample is an increase relative to the reference level. (a) detecting expression of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2 in a biological sample obtained from the patient prior to administration of a VEGF antagonist to the patient; and (b) comparing the expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2 to a reference expression level of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2, wherein a change in the level of expression of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2 in the patient sample relative to the reference level identifies a patient who is likely to respond to treatment with a VEGF antagonist, wherein the change in the level of expression of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2 in the patient sample is an increase relative to the reference level.
Device for the engagement and the disengagement of a power take-off for a vehicle with a trailer , the trailer being operatively connected to the vehicle through a cardan , the device comprising a detection device of data pertaining to the angle (ε) between an arm of the cardan and the projection of the other arm of the cardan beyond the cardan itself and comparison means of the angle (ε) between one cardan arm and the projection of the other arm of the cardan beyond the cardan itself and one or more preset threshold angles (S, S'), apt to disengage the power take-off when said angle (ε) between one cardan arm and the projection of the other arm of the cardan beyond the cardan itself is greater than a threshold angle (S) and to engage it again when said angle (ε) between one cardan arm and the projection of the other arm of the cardan beyond the cardan itself is smaller than another threshold angle (S'), the other threshold angle (S') being equal to or different from the first one, characterized in that said detection device consists of a pair of position determining systems, suitable to be arranged one in the vehicle area and one in the trailer area, and in that the comparison means is configured such that the angle to be compared against the threshold angles is calculated with the formula: ε = 180 ° − arcos 1 / 2 N / M + M / N − L 2 / MN wherein: M is the distance between one position determining system and the cardan joint, N is the distance between the other position determining system and the cardan joint, L is the distance between the two position determining systems, ε is the angle between the arm of the cardan and the projection of the other arm of the cardan beyond the cardan itself. wherein: M is the distance between one position determining system and the cardan joint, N is the distance between the other position determining system and the cardan joint, L is the distance between the two position determining systems, ε is the angle between the arm of the cardan and the projection of the other arm of the cardan beyond the cardan itself.
A filter (100, 200, 300a-300c, 400a-400c, 500, 600a-600c, 1330), comprising: a central filter region (102, 202, 302a-302c, 402a-402c, 502, 602a-602c, 1332), the central filter region (102, 202, 302a-302c, 402a-402c, 502, 602a-602c, 1332) to transmit a first wavelength range (λ1); a peripheral filter region (106, 206, 306, 406a-406c, 506, 606, 1336), the peripheral filter region (106, 206, 306, 406a-406c, 506, 606, 1336) to block a second wavelength range (λ2) and transmit the first wavelength range (λ1); and a transition filter region (104, 204, 204a-206c, 304a-304c, 404a-404c, 504, 604a-604c, 1334) between the central and peripheral filter regions, the transition filter region (104, 204, 204a-206c, 304a-304c, 404a-404c, 504, 604a-604c, 1334) to transmit the first wavelength range (λ1) and - if the central filter region is to block the second wavelength range, to transmit the second wavelength range (λ2), or - if the central filter region is to transmit the second wavelength range, to transmit less of the second wavelength range (λ2) than the second wavelength range (λ2) is to be transmitted in the central filter region, and more of the second wavelength range (λ2) than the second wavelength range (λ2) is to be transmitted in the peripheral filter region. a central filter region (102, 202, 302a-302c, 402a-402c, 502, 602a-602c, 1332), the central filter region (102, 202, 302a-302c, 402a-402c, 502, 602a-602c, 1332) to transmit a first wavelength range (λ1); a peripheral filter region (106, 206, 306, 406a-406c, 506, 606, 1336), the peripheral filter region (106, 206, 306, 406a-406c, 506, 606, 1336) to block a second wavelength range (λ2) and transmit the first wavelength range (λ1); and a transition filter region (104, 204, 204a-206c, 304a-304c, 404a-404c, 504, 604a-604c, 1334) between the central and peripheral filter regions, the transition filter region (104, 204, 204a-206c, 304a-304c, 404a-404c, 504, 604a-604c, 1334) to transmit the first wavelength range (λ1) and - if the central filter region is to block the second wavelength range, to transmit the second wavelength range (λ2), or - if the central filter region is to transmit the second wavelength range, to transmit less of the second wavelength range (λ2) than the second wavelength range (λ2) is to be transmitted in the central filter region, and more of the second wavelength range (λ2) than the second wavelength range (λ2) is to be transmitted in the peripheral filter region. - if the central filter region is to block the second wavelength range, to transmit the second wavelength range (λ2), or - if the central filter region is to transmit the second wavelength range, to transmit less of the second wavelength range (λ2) than the second wavelength range (λ2) is to be transmitted in the central filter region, and more of the second wavelength range (λ2) than the second wavelength range (λ2) is to be transmitted in the peripheral filter region.
A CD40 receptor agonist protein comprising a single-chain fusion polypeptide comprising: (i) a first soluble CD40L domain, (ii) a first peptide linker, (iii) a second soluble CD40L domain, (iv) a second peptide linker, and (v) a third soluble CD40L domain, and (vi) an antibody Fc fragment, consisting of the amino acid sequence as shown in SEQ ID NO: 13 or 14 or amino acids 1-217 of SEQ ID NO: 13 or 14, wherein the antibody Fc fragment (vi) is located C-terminally to the third CD40L domain (v), and is fused to the soluble CD40L domain (v) via a hinge-linker of any one of SEQ ID NOs: 16 and 19-24. (i) a first soluble CD40L domain, (ii) a first peptide linker, (iii) a second soluble CD40L domain, (iv) a second peptide linker, and (v) a third soluble CD40L domain, and (vi) an antibody Fc fragment, consisting of the amino acid sequence as shown in SEQ ID NO: 13 or 14 or amino acids 1-217 of SEQ ID NO: 13 or 14,
A method for maximising energy efficiency of an electric drive system comprising an electric motor and a load, wherein the method characterized by determining speed dependent torque characteristics of the system , wherein the torque characteristics are selected from two types of behaviour: linear or quadratic behaviour of a torque of the motor in respect to a rotational speed of the motor, and controlling the motor on the basis of the determined torque characteristics .
A structured substrate comprising: a first major surface and second major surface, wherein the first major surface and the second major surface each have a microstructured surface, each of the first major surface and the second major surface comprising a plurality of spaced apart protrusions forming a repeating pattern, each repeating pattern having a major axis, wherein the major axis comprises one of the major axes in the translational direction of the repeating pattern, and wherein the major axis of the repeating pattern on the second major surface forms an oblique angle with the major axis on the first major surface, wherein the angle is in the range of 10-90% of the angle of rotational symmetry of the repeating pattern, and wherein the structured substrate is a unitary substrate.